SPRING HOUSE, PA – Johnson & Johnson (NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to the U.S ...

A study published Nov. 14 in Gastroenterology has found a link between inflammatory bowel disease risk and pesticides, along with other environmental pollutants. Manasi Agrawal, MD, a ...

The American Gastroenterological Association (AGA) has released a new clinical guideline on the pharmacological management of ...

Inflammatory Bowel Disease (IBD), encompassing ulcerative colitis (UC) and Crohn’s disease (CD), presents a unique clinical ...

New experimental studies by numerous research groups, including the Max Planck Institute for Evolutionary Biology (MPI-EB) in ...

5. The guidance recommends advanced or immunomodulatory therapy after failure of 5-aminosalicylates instead of a "step-up" approach. The recommendations also define moderate to severe disease using a ...

Johnson & Johnson seeks US FDA approval for subcutaneous induction regimen of Tremfya in ulcerative colitis: Spring House, Pennsylvania Monday, November 25, 2024, 11:00 Hrs [IST] ...

The request is based on findings from the Phase III ASTRO study, which achieved the primary endpoint of clinical remission at ...

Notable news about inflammatory bowel disease (IBD) in 2024 included a study evaluating loss of response to tumor necrosis ...

Johnson & Johnson (JNJ) announced the submission of a supplemental Biologics License Application to the FDA seeking approval of a ...

US healthcare giant Johnson & Johnson has filed a supplemental Biologics License Application with the US Food and Drug ...

AnaptysBio’s drug candidates rosnilimab and ANB032 hold key trial results ahead. Find out why ANAB stock is impacted by ...